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1. Introduction 
Although a moderate increase of reactive oxygen species (ROS) may induce cell 
proliferation, excessive amounts of ROS can cause oxidative damage to lipids, proteins, and 
DNA, provoking oncogenic transformation, increased metabolic activity, and mitochondrial 
dysfunction (Dreher and Junod, 1996; Behrend et al., 2003; Pelicano et al, 2003). Many 
reports suggest that cancer cells are under a continuous oxidative stress (Pervaiz and 
Clement, 2004; Schumacker et al., 2006; Kryston et al., 2011). Studies with human tumor cell 
lines clearly show that these cells produce ROS at a much higher rate than healthy cells 
(Oberley and Buettner, 1979; Lu et al., 2007). ROS have been established as important 
molecules involved in the multistage process of carcinogenesis (Klaunig and Kamendulis, 
2004). Mitochondria are the major consumers of molecular oxygen in cells, representing an 
important source of ROS. It is well accepted that cancer cells present mitochondrial 
alterations which result in respiration injury. This mitochondrial dysfunction may induce a 
low coupling efficiency of the mitochondrial electron chain, increasing electron leakage and 
leading to enhanced ROS formation. The resulting oxidative stress may cause further 
damage to both mitochondrial DNA (mtDNA) and the respiratory chain, amplifying the 
ROS generation (Zorov et al., 2006).  
The higher oxidative stress observed in cancer cells can also result from a decrease or 
inactivation of antioxidants (Huang et al., 2003; Conklin, 2004). The majority of tumor cells 
usually present very few antioxidative enzymes, such as catalase, superoxide dismutase, 
and glutathione peroxidase, which are known to play a protective role against ROS in 
normal cells (Sato et al., 1992; Hasegawa et al., 2002; Pelicano et al., 2004). The lack of proper 
antioxidant defences makes tumor cells very vulnerable to oxidative stress. Nevertheless, 
some studies have revealed increased expression of antioxidants, probably as a consequence 
of selective pressure towards stress adaptation. The sources of ROS in cancer cells and the 
consequences of oxidative stress in the carcinogenesis process are still under debate. 
What seems accepted is that cancer cells have increased ROS steady state level and are likely 
to be more vulnerable to damage by further ROS insults induced by exogenous agents. 
Thus, manipulating ROS levels by redox modulation could be a way to selectively kill 
cancer cells without causing significant toxicity to normal cells. A promising anticancer 
strategy named “oxidation therapy” has been developed by inducing cytotoxic oxidative 
stress for cancer treatment. This could be achieved by two different methods: inducing the 
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generation of cytotoxic levels of ROS, and inhibiting the antioxidant system of tumor cells 
(Fang et al., 2007; Trachootham et al., 2009). 
It is well known that ROS, such as hydrogen peroxide (H2O2) and superoxide anion, induce 
apoptosis to a wide range of tumor cells through the activation of the caspase cascade. It has 
been described that mitochondrial damage induced by the use of certain drugs provokes an 
increment of oxidative stress and cell death (Chandra et al., 2000; Conklin, 2004). Major 
ROS-modulating agents are based on the capacity to induce high ROS generation or to 
reduce the antioxidant defence machinery of cancer cells.  
An interesting drug for oxidative cancer therapy is amitriptyline, a tricyclic antidepressant 
commonly prescribed for depression and therapeutic treatments of several neuropathic and 
inflammatory illnesses. Chlorimipramine, another tricyclic antidepressant, has been already 
proposed as a novel anticancer agent targeted to mitochondria as it induces caspase-3-
dependent apoptosis (Daley et al., 2005). Several reports showed that the toxicity of this drug 
is due to an increase in oxidative stress by the generation of high amounts of ROS (Daley et al., 
2005; Moreno-Fernández et al., 2008; Cordero et al., 2009). Therefore, amitriptyline has being 
proposed to be used for anticancer oxidant therapy against tumors that present significant 
oxidative stress and/or low antioxidant defences (Cordero et al., 2010).  
2. Mitochondria and Reactive Oxygen Species (ROS) 
Mitochondria are dynamic organelles that play a central role in many cellular functions 
including the generation of chemical energy (adenosine triphosphate, ATP), heat, and 
intracellular calcium homeostasis. They are also responsible for the formation of ROS and 
for triggering the programmed cell death or apoptosis (Turrens, 2003). The primary 
metabolic function of mitochondria is oxidative phosphorylation, an energy-generating 
process that couples oxidation of respiratory substrates to the synthesis of ATP (Pieczenik & 
Neustadt, 2007). The mitochondrial respiratory chain (MRC) is composed of five 
multisubunit enzyme complexes. Both the mtDNA and the nuclear DNA (nDNA) encode 
for polypeptide components of these complexes. Electron transport between MRC 
complexes I–IV is coupled to the extrusion of protons across the inner mitochondrial 
membrane by proton pump components of the respiratory chain. This movement of protons 
creates an electrochemical gradient (m) across the inner mitochondrial membrane. 
Protons return to the mitochondrial matrix by flowing through ATP synthase (complex V), 
which utilizes the energy thus produced to synthesize ATP from adenosine diphosphate 
(ADP) and inorganic phosphate. Both the mtDNA and the nDNA encode for polypeptide 
components of these complexes. As a consequence, mutations in either genome can cause 
MRC dysfunction that impairs transport of electrons and/or protons and decreases ATP 
synthesis. Primary or secondary genetic diseases affecting MRC or secondary mitochondrial 
dysfunctions usually affect brain and skeletal muscle because of their energy requirements. 
Besides MRC enzyme complexes, two electron carriers, coenzyme Q10 (CoQ) and 
cytochrome c, are essential for mitochondrial synthesis of ATP. CoQ transports electrons 
from complexes I and II to complex III and is essential for the stability of complex III. CoQ is 
a lipid-soluble component of virtually all cell membranes. CoQ also functions as an 
antioxidant that protects cells both by direct ROS scavenging and by regenerating other 
antioxidants such as vitamins C and E (Turunen et al., 2004). Given the critical role of CoQ 
in mitochondria function, it has been suggested that CoQ levels could be a useful biological 
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marker of mitochondrial function (Haas et al., 2008). CoQ deficiency induces decreased 
mitochondrial respiratory enzymes activity, reduced expression of mitochondrial proteins 
involved in oxidative phosphorylation, decreased mitochondrial membrane potential, 
increased production of ROS, mitochondrial permeabilization, mitophagy of dysfunctional 
mitochondria, reduced growth rates and cell death (Rodriguez-Hernandez et al., 2009, 
Cotan et al, 2011). 
In addition to energy, mitochondrial oxidative phosphorylation also generates ROS. When 
the MRC becomes highly reduced, the excess electrons from complex I or complex III may 
increase substantially, passing directly to O2 to generate high amounts of superoxide anion 
(O2−). Superoxide is transformed to hydrogen peroxide (H2O2) by the detoxification 
enzymes manganese superoxide dismutase (MnSOD) or copper/zinc superoxide dismutase 
(Cu/Zn SOD), and then to water by catalase, glutathione peroxidase (GPx) or peroxiredoxin 
III (PRX III). However, when these enzymes cannot convert ROS such as the superoxide 
radical to water fast enough, oxidative damage occurs and accumulates in the mitochondria. 
If H2O2 encounters a reduced transition metal or is mixed with O2−, the H2O2 can be further 
reduced to hydroxyl radical (HO), the most potent oxidizing agent among ROS. 
Additionally, nitric oxide (NO) is produced within the mitochondria by mitochondrial 
nitric oxide synthase (mtNOS) and also freely diffuses into the mitochondria from the 
cytosol. NO reacts with O2− to produce peroxynitrite (ONOO−). Together, these two 
radicals as well as others can do great damage to mitochondria and other cellular 
components (Turrens, 2003). 
Under normal physiological conditions, ROS production is highly regulated. However, if 
the MRC is inhibited, or key mitochondrial components, such as CoQ, are deficient, then, 
electrons accumulate on the MRC carriers, greatly increasing the rate of a single electron 
being transferred to O2 to generate O2−. An excessive mitochondrial ROS production can 
exceed the cellular antioxidant defense and the cumulative damage can ultimately destroy 
the cell by necrosis or apoptosis. 
Mitochondria play an important role in cell bioenergetics and life signaling. Mitochondria 
are necessary for cell survival but they can also trigger cell death, thus exerting decisive 
control over the biochemistry of several cascades that lead to cell death, specifically the 
intrinsic pathway of apoptosis. The particular biochemical properties of these organelles are 
closely related to their segmented structures, which provide an optimal environment for 
multiple pathways of biosynthesis and bioenergetics. Consequently, it is possible that these 
organelles are involved in the process of carcinogenesis through alterations in cell 
metabolism and cell death pathways (Pilkington et al., 2008). Cancer cells show alterations 
in mtDNA, in oxidative phosphorylation and in energetic metabolism, all triggered by a 
pro-oxidative change (Indo et al., 2007). The “respiratory damage” in cancer cells predicts 
low coupling efficiency in electron transfer at the inner membrane of mitochondria and, 
consequently, greater loss of electrons, leading to the formation of more O2− (Pelicano et al., 
2003). The superoxide anion will thus generate more free radicals. Generated ROS can be 
released into cytosol and trigger “ROS-induced ROS-release” (RIRR) in neighbouring 
mitochondria. This mitochondrion-to-mitochondrion ROS-signaling constitutes a positive 
feedback mechanism for enhanced ROS production potentially leading to significant 
mitochondrial injury (Zorov et al., 2006). Recent studies by a number of groups have 
demonstrated that ROS can directly modify signaling proteins through different 
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modifications, for example by nitrosylation, carbonylation, disulphide bond formation and 
glutathionylation. Moreover, redox modification of proteins permits further regulation of 
cell signaling pathways (England and Cotter, 2005).  
3. Oxidative stress and cancer 
3.1 ROS and carcinogenesis 
In general, oxidative/nitrosative stress could be defined as an imbalance between the 
presence of high levels of ROS and reactive nitrogen species (RNS), and the antioxidative 
defense mechanisms. These toxic molecules are formed via oxidation-reduction reactions 
and are highly reactive since they have an odd number of electrons. ROS generated under 
physiological conditions are essential for life, as they are involved in bactericidal activity of 
phagocytes, and in signal transduction pathways, regulating cell growth and reduction–
oxidation (redox) status (Davies, 1995). ROS includes free radicals, such as hydroxyl and 
superoxide radicals, and non-radicals, including hydrogen peroxide and singlet oxygen. 
Oxidative stress and generation of free radicals, as primary or secondary event, have been 
related in a great number of diseases, including cancer (Floyd, 1990). 
At the beginning of the carcinogenic process, tumor cells accumulate mutations that allow 
them to proliferate in an uncontrolled way. Moreover, these alterations contribute to 
increase the susceptibility to accumulate additional genetic modifications, facilitating tumor 
progression and cancer development. Cancer could be defined as a cell-cycle desease, where 
its misregulation is considered an essential step (Sandhu et al., 2000). Carcinogenesis is a 
complex process of different sequencies that allow a cell to evolve from a healthy state into a 
pre-cancerous state and eventually reach a cancerous state. In this sense, there are several 
theories about the process of carcinogenesis. For instance, an increase of DNA synthesis and 
mitosis triggered by non-genotoxic agents could induce mutations in new cells. These 
mutations could spread through new cell divisions, evolving from an initial pre-neoplastic 
state into a neoplastic state. Another theory explains the existence of an imbalance between 
proliferation and cell death, where proliferation is favoured. If DNA damage is too high, 
there are important mechanisms, such as apoptosis, by which the altered cells are selectively 
eliminated. Protein p53 plays a fundamental role in this process, as it initiates mechanisms 
that eliminate, for example, those oxidized DNA bases that could cause mutations. If cell 
damage is too high, p53 initiates the mechanisms of apoptosis, although uncontrolled 
processes of apoptosis can be harmful for the organism, since healthy cells could also be 
eliminated. Therefore, there are systems for regulating apoptosis that consist of both pro-
apoptotic and anti-apoptotic factors. Alterations that affect the function of gene p53 have 
been found in more than half of all types of cancer. This fact supports the idea that 
carcinogenesis would be caused by an imbalance between proliferation and cell death, in 
favour of proliferation. 
Studies of epidemiology and animal experimentation have shown that carcinogenesis could 
occur in several stages characterized by different mechanisms. Thus, the model of 
carcinogenesis based on the hypothesis of three stages: initiation, promotion and 
progression, should be highlighted. Genotoxic agents are mainly chemical substances that 
damage DNA directly, inducing the generation of a mutation and/or a set of structural 
changes. On the other hand, there is a second category of non-genotoxic carcinogenic agents, 
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whose role in the carcinogenic process is not related directly to DNA damage. These 
compounds modulate mechanisms of cell growth and death. Thus, the development process 
of a cancer would consist of the accumulation of multiple events, and the ROS could act at 
different levels and in all stages (Klauning and Kamendulis, 2004). Thereby, ROS can induce 
both genomic instability, caused by DNA damage, and alterations in cell signaling processes 
related to survival, proliferation, resistance to apoptosis, angiogenesis and metastasis, thus 
contributing to cancer initiation, promotion and progression. 
Initiation involves a DNA mutation that is not lethal, but it produces a cell alteration 
followed by at least one round of DNA synthesis that allows fixing the damage done. At this 
point, the cell can stop its cycle temporally to undo DNA damage and then resume cell 
division. DNA damage may be done by ROS, like hydroxyl radicals formed by the Fenton´s 
reaction. Several studies have revealed an interesting correlation between tumor size and 
the amount of 8-OHdG (8-hydroxy-2'-desoxyguanosine; also known as 8-oxo-
deoxyguanosine, 8-oxo-dG), a nucleotide modified by the activity of free radicals (Kennedy 
et al., 1998; Yano et al., 2009). The promotion stage is characterized by the expansion of 
initiated cells, stimulating cell proliferation and/or apoptosis inhibition. As a result of this 
process, an identificable lesion is formed, thus requiring the constant presence of an agent 
that stimulates promotion. However, it is a reversible process. Many promoter agents have a 
strong inhibitory capacity against antioxidants like catalases, glutathione, SOD, etc. While a 
high level of oxidative stress is cytotoxic for cells and stops proliferation inducing apoptosis 
or even necrosis, moderate levels of oxidative stress may stimulate cell division and, 
therefore, stimulate tumor growth and promotion (Dreher and Junod, 1996). Progression is 
the third and last stage of the carcinogenic process. This stage involves cellular and 
molecular changes that occur from a pre-neoplastic state to a neoplastic state. This stage is 
irreversible and it is characterized by the accumulation of genetic damage that allows the 
cell evolving from benign to malignant.  
ROS are considered as carcinogenic potentials that facilitate cancer promotion and progression 
(Pelicano et al., 2004). The DNA molecule is one of the main targets of free radicals activity in 
the cell, and the modifications performed as a consequence of this activity are relevant for the 
loss of cell homeostasis. This loss may be extended in time due to the DNA functions of 
information reservoir. This is why the agents and mechanisms of damage by ROS are studied 
in depth, because its clarification would lead to elucidate the pathogeny of great morbidity 
and mortality diseases like cancer. There are different types of oxidative damage to DNA, like 
modifications and depurinations of DNA bases, DNA chain ruptures, and mutations, which 
tend to accumulate in an environment with high concentrations of ROS. It is known that DNA 
damage by ROS occurs spontaneously and there is a normal level of bases modified by ROS in 
cellular DNA (Okamoto, 2000). The most frequent modification of DNA linked to ROS is the 
formation of 8-OH-dG, resulting from attack of either a hydroxyl radical or singlet oxygen on 
deoxyguanosine. 8-OH-dG has a highly mutagenic potential, as 5-hydroxymethyl-2-
deoxyuridine (Retel et al., 1993). With relative frequency, the cell will evade DNA damage 
using specific DNA polymerases and enter DNA replication creating mutations and 
chromosomal lesions. Alternatively, the presence of unrepaired DNA lesions can induce cell 
death through the apoptotic pathway. Chronic exposure to DNA lesions can lead to mutations 
and genomic instability (pre-cancerous state) and eventually to malignant transformations 
(cancerous state) (Kryston et al., 2011). 
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3.2 Sources of oxidative stress 
Cells from all organisms are exposed to several oxidizing and harmful agents. These attacks 
can be divided into two groups: exogenous and endogenous. Exogenous sources are related 
to environmental, medical, diagnostic ionizing and non-ionizing radiations (X- or γ-rays, α-
particles from radon decay, UVA radiation) or chemical agents. Endogenous (intracelullar) 
sources of reactive species are primarily produced by O2 metabolism, immune responses 
and inflammation. These processes may result in the production of ROS and RNS that react 
with DNA and produce several lesions and indirect effects. Ionizing radiations can damage 
DNA also by direct energy deposition and ionizations (Kryston et al., 2011). 
Oxygen metabolism is the major source of ROS in tumor tissues. ROS are continously 
formed in mitochondria as respiration byproducts. Cancerous cells are metabolically very 
active and require a great supply of ATP in order to maintain proliferation and cell growth 
under control. This high energy demand in the mitocondrial respiratory chain contributes to 
the generation of ROS. Usually, ATP is produced with high efficiency through oxidative 
phosphorylation in mitochondria. However, a malfunction of mitochondrial respiration is 
usually observed in neoplastic cells due to deletions/mutations in mtDNA, to the aberrant 
expression of some enzymes involved in energy metabolism and to hypoxia (Xu et al., 2005; 
Verrax et al., 2008). On the other hand, the increase of glycolysis in tumor cells has been 
shown to be related to the aggressiveness of the tumor (Cuezva et al., 2002). Acquiring a 
glycolytic phenotype represents a key element for cancer survival and progression, while 
glycolysis inhibition could be proposed as a goal in antitumor therapy (Pelicano et al., 2004). 
In this sense, glucose deprivation in laboratory models has been shown to be related to an 
increase of oxidative stress in tumor cells (Spitz et al., 2000). In cell lines of breast carcinoma, 
glucose deprivation leads to an intracellular increase of pro-oxidants, a decrease of free 
radical neutralization, and pyruvate depletion, which leads to an increase of oxidative stress 
(Spitz et al., 2000; Lee et al., 1999). As a compensation mechanism, glucose deprivation 
induces the expression of heme oxigenase-1 (HO-1), an enzyme that plays an important role 
in the antioxidant defense system of the organism and in Fe homeostasis. Chang and 
collegues (Chang et al., 2003) showed that the generation of ROS in mitochondria induces 
the overexpression of HO-1, which demonstrates that this is a common mechanism of 
regulation with the aim of protecting cells against oxidative damage.  
As already mentioned, immune response and inflamation are other sources of ROS. It is 
known that oxidative stress activates inflammatory pathways leading to transformation of a 
normal cell to tumor cell, tumor cell survival, proliferation, insensitivity to anti-growth 
signaling, invasion, sustained angiogenesis, and stem cell survival (Reuter et al., 2010). 
Chronic inflammation is triggered by environmental (extrinsic) factors (eg, infection, 
tobacco, asbestos) and host mutations (intrinsic) factors (eg, Ras, Myc, p53). Activation of 
Ras, Myc, and p53 cause mitochondrial dysfunction, resulting in mitochondrial ROS 
production and downstream signaling (eg, NFkappaB, STAT3, etc.) that promote 
inflammation-associated cancer (Kamp at al., 2011).  
On the other hand, during immune responses of many carcinogenetic processes, several 
immune-related cells play their roles, like intratumoral lymphocytes killing malignant cells 
and macrophages and neutrophils degrading cells by using oxidants and enzymes. One of 
these enzymes is NADPH oxidase, which activity produces ROS. The increased intensity of 
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oxidative stress helps tumor to go on to malignancy. As an example, in vitro data suggest 
that in environments with certain levels of oxidative stress some cytokines, such as 
interleukin-2 (IL-2) or interferon α (IFNα), induce a decrease of T-lymphocytes or natural 
killer cells, which could suposse a tumor evasion to the immune response (Mantovani et al., 
2003). Another source of free radical generation, usually underestimated but highlighted by 
Kryston et al. (2011), is the chronic exposure to viral infections; as in the case of hepatitis 
viruses, where there is a connection between chronic infection and induction of oxidative 
stress. There is a variety of viruses associated with increased ROS levels, DNA damage and 
mutagenic rate. The high intracellular oxidation status in viral infections consists of 
decreased antioxidant enzymes like catalase, glutathione peroxidase, glutathione reductase 
as well as high level of hydroxyl radicals (Kryston et al., 2011).  
3.3 Influence of ROS in the cell cycle 
Since some time already, an increase of ROS and an altered redox state has been observed in 
cancerous cells (Trachootham et al., 2009). It is known that ROS may serve as cellular 
messengers in the signal translation pathway and also an increase of ROS may trigger cell 
growth and proliferation, contributing to cancer development (Filomeno et al., 2005). 
Uncontrolled tumor cell proliferation requires the up-regulation of multiple intracellular 
signaling pathways, including cascades involved in survival, proliferation, and cell cycle 
progression. The most significant effects of oxidants on signaling pathways have been 
observed in the MAPK/AP-1 and NF-κB pathways (Muller et al., 2010). At the advanced 
stage of the disease, cancerous cells usually show genetic instability and a sharp increase of 
ROS, which induces to genetic mutations and failures in metabolic functioning, provoking a 
greater generation of ROS (Pelicano et al., 2004). Several mechanisms may lead to oxidative 
stress in cancer patients, such as altered energy metabolism, overproduction of cytokines, 
which in turn may increase ROS production, and the use of anti-neoplastic drugs. Altered 
energy metabolism in cancer may explain symptoms such as anorexia/cachexia, nausea and 
vomiting, which prevent normal nutrition. This deficit in the normal supply of nutrients like 
glucose, proteins, antioxidants and vitamins, leads eventually to the lack of antioxidant 
defenses for controlling free radical production.  
Protein p53 is known as “the guardian of the genome” because it is essential for maintaining 
its integrity. This tumor suppressor protein has a fundamental role at detecting and 
eliminating oxidative damage in nuclear and mitochondrial DNA, at preventing mutations 
and at genetic instability. On the other hand, p53 acts also as a transcription factor that 
regulates the expression of many pro-oxidants and antioxidant genes. The functional loss of 
p53 is related to redox disequilibrium, increase of ROS, greater mutagenesis and tumor 
growth (Attardi and Donehower, 2005). This loss of p53 function is observed in many 
human cancers, especially in advanced stages (Bourdon, 2007).  
There is evidence that the increase of ROS in tumor cells has a fundamental role in the 
acquisition of cancer characteristics (Hanahan and Weinberg, 2011): immortalization and 
transformation, cell proliferation and mitogenic signals, and cell survival and interruption of 
apoptotic death. Interestingly, in contrast to the effect of tumor promotion, recent studies 
suggest that the high ROS level has a role in the induction and maintenance of the 
senescence induced by tumor suppression, through the supported activation of the cell cycle 
inhibitor p16 (Ramsey and Sharpless, 2006; Takahashi et al., 2006). On the other hand, if the 
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ROS level increases up to a specific threshold that is incompatible with cell survival, ROS 
can exert cytotoxic effects that lead to the death of malignant cells and, therefore, limit 
cancer progression. This double game of ROS effect on cancerous cells may be used for 
developing new antitumor drugs that provide an increase of lethal oxidative stress in tumor 
cells, which are more sensitive to this type of attack than normal cells. 
3.4 Angiogenesis induced by ROS 
In addition to alterations in the cell cycle, an important event in the growth of any tumor is 
the generation of a new blood supply system that feeds the malignant cells. Migration, 
proliferation and tubular formation by endothelial cells are essential events in the process of 
angiogenesis. It has been suggested that ROS play an important role in angiogenesis, 
although their molecular mechanism remains unknown (Ushio-Fukai, 2004). The vascular 
endothelial growth factor (VEGF) triggers angiogenesis by stimulating the proliferation of 
endothelial cells and their migration through the receptor 2 (Flk1/KDR) of VEGF, which has 
tyrosine kinase activity. ROS derived from NAD(P)H oxidase are important for in vitro 
VEGF signaling and for in vivo angiogenesis. Arbiser and collegues (Arbiser et al., 2002) 
showed that ROS increased the expression of the VEGF, triggering the promotion of 
vascularization mechanisms and the fast expansion of tumors. On the other hand, greater 
metastatic capacity has been associated with high ROS levels in most tumors (Ishikawa et 
al., 2008). So, exogenous administration of ROS could increase certain metastatic states, 
while a treatment with antioxidants could slow down the metastatic progression (Ferraro et 
al., 2006). 
Hypoxia seems to be the most important mechanism for tumor progression through the 
activation of angiogenesis, which is essential for the tumor growth (Harris, 2002). The 
neoplastic cells respond to hypoxia with an increase of ROS level; this occurs in the first 
stages of tumor development as a consequence of the blood supply deficit (Denko et al., 
2003). It was shown that despite hypoxia there was a greater production of ROS, a paradox, 
since the oxygen availability for the formation of O2− would be limited. Perhaps the 
generation of ROS occurs later, throughout tumor development, at the first stages of 
angiogenesis. When the hypoxia of a tumor is followed by blood supply reperfusion, high 
levels of ROS are generated; something similar occurs in a myocardial infarction or a brain 
ischemia.  
3.5 ROS and tumor cell invasion 
Tumor invasion and metastasis are two important events in cancer in which oxidative stress 
has shown to have an important role. When mammalian carcinoma cells are treated with 
hydrogen peroxide before intravenous injection into mice, an increase in lung metastasis 
formation is observed (Kundu et al., 1995), probably due to a decreased attachment of tumor 
cells to the basal lamina or it could alternatively be due to the increased activity or 
expression of proteins that regulate cellular motility. 
On the other hand, the matrix metalloproteinases (MMPs) have been involved in the 
invasion and metastasis of malignant tumors of various histogenetic origins, and are capable 
of cleaving most components of the basement membrane and extracellular matrix 
(Westermarck et al., 1999). The activation of MMPs, such as MMP-2, probably occurs by the 
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reaction of ROS with thiol groups in the protease catalytic domain, being also ROS involved 
in MMP gene expression (Rajagopalan et al., 1996). 
Recently, a number of steps in the progression of metastatic disease have been shown to be 
regulated by redox signaling (Diers et al., 2010). One such redox signaling molecule is the 
electrophilic cyclopentenone prostaglandin, 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), 
which can affect redox signaling through the posttranslational modification of critical 
cysteine residues in proteins such as actin, vimentin, and tubulin. The fact that 15d-PGJ2 can 
alter the cytoskeleton coincides with decreased migration and increased focal-adhesion 
disassembly, which might have important implications in the inhibition of metastatic 
processes such as invasion, intravasation, and extravasation (Diers et al., 2010). 
3.6 ROS adaptation by cancer cells 
There is sufficient evidence that cancer cells are under greater oxidative stress (Pervaiz and 
Clement, 2004; Kryston et al., 2011). High levels of oxidative stress have been found in 
cancer patients (McEligot et al., 2005; Lu et al., 2007), and it has been reported that different 
biomarkers of oxidative-stress-mediated events are elevated in cancer-prone tissues (Bartsch 
and Nair, 2000). In vitro studies clearly show that human tumor cell lines produce ROS at a 
much higher rate than non-transformed cells (Oberley and Buettner, 1979; Lu et al., 2007). In 
cancerous cells, a high level of oxidative stress is observed, which may result not only from 
the overproduction of ROS, but also from low levels or inactivation of antioxidants (Huang 
et al., 2003). Antioxidants are molecules capable of slowing down or even preventing the 
oxidation of other molecules and play an essential role at protecting cells against ROS 
aggression. Inhibition of these enzymes seriously endangers the capability of cells to face 
ROS activity. The first frontier of cellular defense against ROS damage consists of 
endogenous non-enzymatic radical scavengers like glutathione (GSH) and vitamins like C, 
E, antioxidant enzymes like SOD, catalase and GPx, as well as specific repair pathways 
(Kryston et al., 2011). 
A decrease of mitochondrial activity and an overexpression of Mn-SOD with a greater 
production of O2− have been detected in some colorectal carcinomas and tumor cells of the 
pancreas (Van-Driel et al., 1997; Cullen et al., 2003). The accumulation of anion O2− 
stimulates cell growth by altering the redox states of transcription factors and regulators of 
the protein cell cycle. The increase of ROS in tumor cells may induce an increase of 
endogenous antioxidants in order to avoid intracellular lesions. On the contrary, a decrease 
of SOD activity was detected in blood cells of patients with cervical cancer. The decrease of 
SOD activity observed could be related to the generation of free radicals that cause direct 
damage to the enzyme by reticulation or mutation induction (Manoharan et al., 2004; Naidu 
et al., 2007). Besides, this decrease may be caused by an alteration of the oligoelements 
(essential trace elements) that act as cofactors of this enzyme, which may be considered as a 
risk factor of tumor growth or carcinogenesis (Naidu et al., 2007). On the other hand, it was 
observed that the increase in the intensity of oxidative stress in the blood of patients with 
ovarian cancer is accompained by a decrease of antioxidants like SOD, catalase, vitamin C 
and vitamin E (Senthil et al., 2004). A high percentage of tumors show low catalase activity, 
which means an advantageous adaptation for the tumor, which continues to benefit from 
the high levels of ROS. Although oxidant agents can be toxic to normal cells, the moderate 
increase of ROS contributes to the growth and survival of many cancers. 
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The strategy adopted by each type of tumor to increase the intensity of oxidative stress may 
vary from an increase of ROS to a decrease of antioxidants, going through a combination of 
both. The concentration of ROS in the tumor cell must be compensated with that of 
antioxidants in order to obtain an increase of ROS steady state level without reaching lethal 
levels. However, alterations in the mechanisms of antioxidant production are considered as 
indicators of oxidative stress in several types of cancer (Schumacker, 2006). Cancerous cells 
may adapt to survive at certain levels of oxidative stress. For example, greater levels of O2− 
and H2O2 were observed in cells transformed with H-ras, showing high levels of 
antioxidants like peroxiredoxin-3 and thioredoxin peroxidase, compared to normal cells 
(Young et al., 2004). These adaptive mechanisms keep ROS levels in a distribution space that 
allows cancerous cells to avoid serious oxidative damage and to survive ROS-mediated 
stress and mutations. Redox adaptation may be crucial not only for cancer development, but 
also for drug resistance (Pervaiz and Clement, 2004; Sullivan and Graham, 2008). Redox 
adaptation, through the increase of endogenous antioxidants and the activation of the cell 
survival pathway, may confer greater capacity for tolerating the action of exogenous stress, 
with capacity for increasing DNA repair and decreased apoptosis. Thus, although cancerous 
cells are under chronic oxidative stress, they possess remodeled antioxidant system which 
let them to avoid deleterious ROS effects. 
4. Antitumor oxidative therapy 
4.1 The strategy 
The therapeutic selectivity and avoiding resistance to drugs are two important issues in the 
therapy against cancer. Strategies for improving therapeutic selectivity depend largely on 
understanding the biological difference between cancerous and normal cells. Tumor cells, 
compared to normal cells, are under greater oxidative stress related to the oncogenic 
transformation, to alterations in metabolic activity and to an increase of ROS generation 
(Toyokuni et al., 1995; Hileman et al., 2003; Behrend et al., 2003). The high concentration of 
ROS in cancerous cells may have beneficial consequencies, like the stimulation of cell 
proliferation, mutation multiplication, genetic instability and alterations in the sensitivity to 
agents against cancer. However, because ROS are chemically active and may inflict serious 
cell damage, the very fact that cancerous cells usually show greater intrinsic oxidative stress 
may itself provide a unique opportunity to kill tumor cells according to the vulnerability of 
ROS action.  
In this sense, the high concentration of ROS could function as a double-edged sword. A 
moderate increase of ROS could trigger both proliferation and differentiation, as well as 
other tumor characteristics. However, when ROS levels increase up to the lethal threshold it 
may break through the antioxidant capacity of the cell and trigger its death, by apoptosis or 
necrosis, depending on the degree of oxidative damage. Under physiological conditions, 
normal cells maintain redox homeostasis with a low level of basal ROS by controlling the 
equilibrium between the generation of ROS (pro-oxidant) and their elimination (antioxidant 
capacity). Exogenous agents that increase the generation of ROS or decrease the antioxidant 
capacity of cancerous cells will move the redox equilibrium and induce a general increase of 
ROS levels, which will cause cell death when exceeding the tolerance threshold (Figure 1). 
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Fig. 1. Biological basis for therapeutic selectivity in oxidative therapy against cancer cells. 
Adapted from Gupte et al., 2009 and Trachootham et al., 2009.  
Anticancer therapies aimed at the mitochondria of tumor cells are being developed in 
present years, since these organelles are involved in cell death (Daley et al., 2005; Nguyen 
and Hussain, 2007; Ozben, 2007; Pilkington et al., 2008). Mitochondria are the greatest 
oxygen consumers in the cell and they are an important source of reactive oxygen 
mediators. A drug that damages these organelles would cause an increase in ROS 
production and cell death. Currently, there is an anticancer strategy at its peak known as 
“oxidative therapy”, which consists of inducing high ROS steady state levels in tumor cells. 
This therapy may be carried out in two different ways: causing the generation of high levels 
of ROS in solid tumors and inhibiting the antioxidant system of tumor cells (Fang et al., 
2007; Trachootham et al., 2009). It is well established that high levels of ROS, like H2O2 and 
O2−, induce apoptosis in a wide variety of tumor cells activating the caspase cascade 
(Matsura et al., 1999; Yamakawa et al., 2000). 
4.2 Cell death by ROS increment 
Neoplastic cells are metabolically more active and require a high supply of ATP in order to 
keep cell growth and proliferation under control. This high energy demand in the MRC 
leads to the increase of ROS generation (Behrend et al., 2003). The excessive production of 
ROS may damage several cellular components like DNA, proteins, lipids and cell 
membranes. The oxidation of mitochondrial lipids and proteins causes the permeabilization 
of the mitochondrial membrane, which leads to an alteration of the coupling efficiency of 
the electron transport chain, resulting in the generation of more free radicals, and the release 
of cytochrome c, activating the process of programmed cell death (apoptosis) which 
depends on caspases (Conklin, 2004). There is evidence that the main mechanism by which 
oxidant agents may kill cells is the activation of apoptosis. In some cases, the high levels of 
ROS generated may inhibit apoptosis at a caspase level and divert the process toward 
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necrosis (Chandra et al., 2000). The change from apoptosis to necrosis is critical in solid 
tumors and requires considerable amounts of ROS, a decrease of ATP and alterations in the 
mitochondrial electron-transport chain (Lee et al., 1999). The harmful consequences of this 
change lie in the inflammation caused by the rupture of necrotic cells and later release of 
enzymes that degrade the tissues. Thereby, death by apoptosis is preferred in antineoplastic 
therapies. Apoptotic cells cause the least damage to nearby tissues, since they do not release 
their content and are phagocytosed by macrophages.  
Cancerous cells evolve with the mediation of endogenous and exogenous oxidative agents, 
depending on the cell type and the evolution state of the tumor. Tumors adapt to these 
conditions through the development of powerful antioxidant mechanisms and even by the 
use of endogenous ROS for proliferation. When ROS levels increase above the tolerance 
threshold, death of tumor cells is induced. Therefore, the fact that an excess of ROS causes 
cell damage and even death by apoptosis provides us with a strategy for eliminating 
cancerous cells, which are more sensitive to exogenous oxidative stress than normal cells, 
through the generation of free radicals, induced by oxidant pharmacological agents. In some 
cases, tumor cells attacked with antineoplastic therapies may gain resistance to oxidative 
stress, which is why combined therapies are promising, and are intended to converge 
toward improving the oxidative action above the critical threshold, or gathering different 
cytotoxic mechanisms.  
Unfortunately, antitumor therapies may exert harmful effects on normal tissues, partially 
caused by ROS, which limits the application dose and its antitumor activity. Overcoming these 
secondary effects, without altering the therapy efficiency, is a priority and a challenge in 
biomedical research. In this sense, great importance is given to targeted therapies, using 
vehicles (liposomes, nanoparticles) that recognize specific molecules expressed in tumor cells.  
4.3 Antioxidants in oxidative therapy against cancer 
Antioxidants play an essential role in cell protection against ROS. The oxidation of 
antioxidant enzymes reduces the capacity of cells to eliminate free radicals. An important 
approach in the antitumor therapeutic strategies is to inhibit the antioxidant systems, like 
catalase, SOD and GPx, which are the main defense lines of the cell. The inhibitors of 
different antioxidant enzymes have been characterized by their capacity for eliminating 
neoplastic cells, alone or combined. It has also been described that many pharmacological 
agents may have more than one mechanism of action and affect multiple biological 
processes. There are agents that induce apoptosis which are oxidant and others that 
stimulate cell metabolism. On the other hand, there are apoptosis inhibitors that have 
antioxidant activities. In the absence of adequate antioxidant defenses, the damage from 
oxidative stress leads to the activation of the genes responsible for apoptosis. 
There are conflicting data in the results obtained by different researchers regarding the 
levels of antioxidants in tumor tissue and in blood from cancer patients. In some cases, there 
are differences between different antioxidants in the same patient; some increase and others 
decrease (Ray et al., 2000). In breast cancer, for example, several studies describe an increase 
of lipid peroxidation and a decrease of antioxidants (Khanzode et al., 2004; Sener et al., 
2007). However, other studies performed in neoplastic tissues have shown a greater 
presence of ROS and a high expression of antioxidants (Oltra et al., 2001; Gönenç et al., 
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2006). So, for instance, an increase in the expression of Mn-SOD has been observed in breast 
cancer and in blood samples from patients with different types of leukemia (Nishiura et al., 
1992; Devi et al., 2000; Ray et al., 2000). This fact may reflect an adaptive mechanism by 
which cancerous cells respond to an increase of ROS levels produced in mitochondria. ROS 
can induce the over-regulation of Mn-SOD through the modulation of the redox states of the 
transcription factors (AP- 1, NF-kappaB). Due to its high expression in certain types of 
cancer, Mn-SOD has been considered as a tumor marker (Schadendorf et al., 1995). This 
expression of SOD protects tumor cells against a lethal increase of ROS levels. In fact, it has 
been demonstrated that the inhibition of SOD with 2-methoxyestradiol would induce 
apoptosis in leukemia cells through a mechanism mediated by free radicals, without 
showing significant toxicity in normal lymphocytes (Zhou et al., 2003). 
Antitumor therapies mediated by ROS show a promising therapeutic activity in clinical 
studies (Trachootham et al., 2009). However, some tumor cells, especially in advanced 
stages of the disease, have adapted to oxidative stress due to their antioxidant capacity. This 
redox adaptation does not only allow tumor cells surviving under high levels of ROS, it also 
provides an increase of survival molecules and a greater capacity for drug inactivation. 
Moreover, it has been suggested that resistance to the agents that induce intracellular ROS 
production, such as paclitaxel, doxorubicin or other drugs, is correlated to the increase of 
antioxidants (Glorieux et al., 2011). Thereby, the capability of certain drugs to inhibit or 
reduce the antioxidant machinery is very useful in oxidative therapy. These drugs could be 
used in combination with oxidant agents for greater efficiency in antitumor therapies. 
5. Amitriptyline as an anti-cancer agent 
Amitriptyline is a commonly prescribed tricyclic antidepressant drug that is well known to 
death investigators, forensic pathologists, and toxicologists. Amitriptyline has sedative 
effects and is frequently prescribed for patients experiencing symptoms of depression. 
Amitriptyline, have also been used for therapeutic treatment of neuropathic and 
inflammatory diseases such as fibromyalgia, chronic fatigue syndrome, migraine, irritable 
bowel syndrome, and atypical facial pain (Gruber et al., 1996). Besides its anxiolytic 
properties, amitriptyline has central anticholinergic effects. Amitriptyline inhibits serotonin 
and noradrenaline uptake in presynaptic nerve ending (Maubach et al., 1999). However, 
toxicity of amitriptyline has been observed during standard treatments, and frequently 
during suicidal or accidental overdosage. Tricyclic antidepressant overdosage has toxic 
effects over cardiovascular, autonomous nervous, and central nervous systems, and may 
result in cardiotoxicity, cardiac conduction delays, dysrhythmia, hypotension, altered 
mental status, and seizures (Thanacoody and Thomas, 2005; Kiyan et al., 2006).  
In vitro administration of amitriptyline to cell cultures induces several signs of toxicity. 
Amitriptyline treatment induces alteration of cellular permeability based on its detergent 
nature (Kitagawa et al., 2006). Furthermore, amitriptyline causes alterations in the glucidic 
metabolism of neurons resulting in a decrease of both uptake and transport of glucose 
(Mannerstrom and Tahti, 2004). Additionally, amitriptyline provokes an increase of 
intracellular lipid peroxidation in mouse 3T3 fibroblasts (Viola et al., 2000) and some mouse 
tissues (Bautista-Ferrufino et al., 2011), and many of these toxic effects are prevented by 
antioxidants (Slamon and Pentreath, 2000). Recently, our group has shown that 
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amitriptyline induced toxicity is caused through a mitochondrial dysfunction, and increased 
ROS level (Moreno-Fernandez et al., 2008; Cordero et al., 2009). Amitriptyline reduced 
significantly the number of cultured cells; enhanced the production of stimulated lipid 
peroxidation, inverting the lipid reduced/oxidized ratio; decreased catalase protein levels,  
cytochrome c, ΔΨm, and citrate synthase activity; revealing mitochondrial damage. So, 
amitriptyline-induced toxicity is caused through mitochondrial dysfunction, and increased 
mitochondrial ROS production. Moreover, CoQ level was decreased by amitriptyline 
treatment and CoQ and alpha-tocopherol supplementation ameliorated amitriptyline-
induced toxicity in both cultured human primary fibroblasts and zebrafish embryos 
(Cordero et al., 2009).  
Other toxic effects attributed to amitriptyline lie in the alteration of neuron carbohydrate 
metabolism, which results in a decrease of glucose absorption and transport; causing a total 
loss of neuron viability in a cell line of neuroblastoma (Mannestrom et al., 2004). 
Recent studies have shown that some antidepressants can kill cancerous cells. In fact, 
tricyclic antidepressants have shown to cause cell death in human normal lymphocytes 
(Karlson et al., 1998), Hodgkin´s lymphoma cells (Serafeim et al., 2003), neurons (Lirk et al., 
2006), glioma cells (Xia et al., 1999; Daley et al., 2005; Levkovitz et al., 2005) and colorectal 
cancer cells (Arimochi y Morita, 2006). Chlorimipramine exerts its effect via the inhibition of 
complex III of the MRC (Daley et al., 2005). The same is valid for amitriptyline, as we have 
already reported (Cordero et al., 2009). We showed in fibroblasts treated with amitriptyline 
a decrease of expression level of proteins of complex I, complex III, cytochrome c, and 
reduced CoQ10 levels. Deficient mitochondrial protein expression levels and reduced levels 
of CoQ10 may impair normal mitochondrial electron flow and proton pumping, inducing a 
drop in respiratory complexes activity, and mitochondrial membrane potential. Our data 
showed that amitriptyline-treated fibroblasts have reduced NADH:cytochrome c reductase 
(complex I+III) activity, and lower mitochondrial membrane potential, which may 
contribute to impaired mitochondrial protein import and aggravate mitochondrial 
dysfunction, ROS production, and oxidative stress. It has been proposed that ROS damage 
can induce the mitochondrial permeability transition (MPT) by the opening of non-specific 
high conductance permeability transition (PT) pores in the mitochondrial inner membrane 
(England and Cotter, 2005). This, in turn, leads to a simultaneous collapse of mitochondrial 
membrane potential. The activation of MPTcauses mitochondria to become permeable to all 
solutes up to a molecular mass of about 1500 Da (Forte and Bernardi, 2005). After MPT, 
mitochondria undergo a dramatic swelling driven by colloid osmotic forces, which 
culminates in the rupture of the outer membrane and release of proapoptotic mitochondrial 
intermembrane proteins into the cytosol, such as cytochrome c, apoptosis inducing factor, 
Smac/Diablo, and others (Cordero et al.,2009).  
We have also studied the effect of amitriptyline on tumor cell lines (Cordero et al., 2010). We 
observed that this drug induced important mitochondrial damage in tumor cell lines (H460: 
non-small cell lung cancer, HeLa: epithelial cervical cancer, and HepG2: hepatoma), 
generating high amounts of ROS and provoking apoptotic cell death. Moreover, 
amitriptyline effects have been compared with three antitumor drugs frequently used in 
cancer therapy: camptothecin (CPT), doxorubicin (Doxo), and methotrexate (Metho). 
Interestingly, amitriptyline induced significantly higher ROS generation in comparison with 
the other drugs, producing a dose-dependent increase of apoptosis in human cancer cells 
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through a mechanism dependent on caspase-3 activation. Apoptosis percentage was 
significally higher in those cells treated with amitriptyline than in cells treated with CPT, 
Doxo or Metho (Figure 2A). Moreover, when the cell cycle of synchronized cultures was 
stopped at the G0/G1 phase by depriving cells from serum, the difference of apoptosis 
percentage among amitriptyline and the remaining drugs was significantly higher than in 
normal cultures (Figure 2B). These results suggest that the effect of amitriptyline does not 
depend on cell cycle stage, whereas CPT, Doxo, and Metho are more harmful in dividing 
cells, as most chemotherapeutic drugs. These data are of special interest for cancer treatment 
during the nongrowing phases of certain tumors. 
 
Fig. 2. Comparative study of amitriptyline and different chemotherapeutic drugs for the 
evaluation of apoptosis. (A) Percentages of apoptotic cells in H460 cell cultures 24 h after 
administration of drugs at different concentration. (B) Apoptosis assessment in 
synchronized cultures stopped at the G0/G1 phase. Adapted from Cordero et al., 2010.  
After treating cancer cells with amitriptyline, we have found increased ROS level and 
several signs of mitochondrial damage, as attenuated complex I+III activity, decreased 
protein levels of complex III, decreased membrane potential, and a significant reduction of 
the number of this organelle, shown by cytochrome c and citrate synthase determination, 
and electron microscopy (Figure 3). So, this tricyclic compound provokes oxidative stress in 
cancer cells, being mitochondria the target of its toxicity. None of the chemotherapeutic 
drugs tested seemed to damage mitochondria seriously. However, the chemotherapeutic 
drugs induced apoptosis and increased ROS production in tumor cells, although not with 
the intensity of amitriptyline. 
According to our data, amitriptyline induces a mitochondrial damage characterized by a 
decrease of the expression levels of complexes I and III of the MRC as well as of cytochrome 
c and of CoQ levels, which suggests an alteration in the activity, organization and assembly 
of the mitochondrial complexes, being this reflected in a decrease of the electron flow as 
well as a decrease of the mitochondrial membrane potential and, therefore, an increase of 
intramitochondrial ROS prodution. The damage caused by the increase of mitochondrial 
ROS induces the opening of the mitochondrial permeability transition pore (MPT), thus 
increasing mitochondrial permeability with the consequent release of proapoptotic proteins 
to the cytosol such as cytochrome c, Smac/Diablo, etc., initiating the intrinsic pathway of 
apoptosis dependent on caspase-3 (Figure 4).  
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Fig. 3. Transmission electron microscopy showing damage and fewer mitochondria in H460 
cells treated with 50 mmol/l of amitriptyline. Degenerating mitochondria (arrows) are 
observed in treated tumor cells. (A) Nontreated tumor cells. (B) Amitriptyline-treated tumor 
cells (Cordero et al., 2010).  
In general, the increase of ROS production causes, as a response, an increase of the 
antioxidants activities. However, under the high input rate of ROS, enzyme inactivation 
prevails, which leads to the reduction of antioxidant enzymes activity and to the process of 
oxidative damage. Thus, tumor cells frequently possess very little antioxidative enzymes, such 
as catalase, SOD, and glutathione peroxidase, which are known to play a protective role 
against ROS in normal cells. We have observed in normal fibroblast treated with amitriptyline 
a decrease in protein expression of antioxidant enzymes (catalase and MnSOD) 16 h after the 
treatment, followed by restored levels after 24h, as a mechanism of antioxidant defense 
(Moreno-Fernández et al., 2008). Interestingly, in cancer cells, the same concentration of 
amitriptyline provoked an unrestorable decrease of catalase (Cordero et al., 2010). The 
difference of the antioxidant status observed in cancer cells, in comparison with healthy 
fibroblasts, may be caused by the lower antioxidant level present in the cancer cell lines used. 
Besides the decrease of catalase and MnSOD, amitriptyline also produces a significant 
decrease of CoQ level in tumor cells (Cordero et al., 2010). CoQ plays a critical protective role 
by either acting as an antioxidant or by the noncompetitive inhibition of the neutral 
sphingomyelinase of plasma membrane, preventing ceramide production (Mates et al., 1999). 
Most chemotherapeutic drugs do not provoke any decrement of antioxidants. Instead, they 
frequently induce an increase of antioxidants as a protecting mechanism against ROS 
generation, leading to lower cell death (Brea-Calvo et al., 2006). The fact that amitriptyline 
downregulates both catalase and CoQ activity is very interesting since it destroys the already 
decreased antioxidant defenses present in cancer cells, making the oxidative stress produced 
by the amitriptyline-induced ROS generation a more effective weapon.  
Thus, amitriptyline promotes enhanced oxidative damage to cancer cells as this drug attacks 
cells by two different mechanisms: by the production of a high amount of ROS, provoking 
apoptosis; and by a significant decrease in antioxidant levels, seriously limiting cell reaction 
to oxidative stress. Therefore, amitriptyline could be used for anticancer oxidant therapy 
against tumors that present significant oxidative stress and/or low antioxidant defenses. For 
anticancer therapeutics on those tumors with a similar redox status than normal cells, a drug 
delivery vehicle should be used. 
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Fig. 4. Mechanism of apoptosis induction by amitriptyline.  
6. Conclusion 
Evidence exists that cancer cells are under a continuous oxidative stress, facilitating ROS to 
act as carcinogen, as they were shown to be involved in mutagenesis, cancer promotion and 
progression. On the other hand, ROS may promote either cell proliferation or cell death, 
depending on the rate of ROS production and the activity of the antioxidant system. 
Accordingly, oxidative therapy against cancer arises as a ROS-generating strategy which 
increase oxidative status above the critical threshold required for cell survival.  
In our studies, the tricyclic antidepressant amitriptyline induced high ROS generation as a 
result of mitochondrial dysfunction, provoking a higher level of apoptosis of tumor cells 
than common chemotherapeutic drugs. Moreover, it inhibits important antioxidants of the 
cell-defense machinery, dramatically limiting tumor cell response to ROS production. Thus, 
amitriptyline, as well as other tricyclic compounds, is being assayed as an anti-cancer drug 
in oxidative therapy. 
Unfortunately, oxidative anti-cancer therapy may exert harmful effects on normal tissues, 
limiting the applicable dose of drugs and anti-tumor activity. So, differences in ROS-
induced cell death and oxidative status between normal and neoplastic cells from different 
cancer types must be thoroughly investigated, taking into account the complexity of 
physiological and pathological pathways involved in redox balance. On the other hand, it is 
not strange that after ROS-generating therapies cancer cells achieve further resistance to 
oxidative stress. In consequence, combination therapies could be achieved in order to either 
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increase the intensity of oxidative stress above the critical threshold, or to perform different 
cytotoxic mechanisms. 
Nevertheless, although greater efforts must be made, oxidative therapy against cancer is a 
promising strategy that is worthy of being investigated.  
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